DOI: https://doi.org/10.22263/2312-4156.2025.3.59
K.A. Liasnikau, Y.A. Shliakhtunou
Individualization of adjuvant chemotherapy in patients with stage IA-IIB non-small cell lung cancer taking into account circulating tumor cells and its cost-efficiency
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2025;24(3):59-65.
Abstract.
The article presents the analysis of the cost-effectiveness of personalized adjuvant chemotherapy in patients with non-small cell lung cancer based on the determination of BIRC5+ circulating tumor cells (CTCs) in the peripheral blood. Three months after surgery, the group nunbering 22 patients at risk for disease recurrence was identified, who were potentially eligible for adjuvant chemotherapy. The economic effect is calculated for a hypothetical cohort of 22 patients. The cost of adjuvant therapy, which is prescribed when CTC is detected in the peripheral blood, is approximately 18163.2 USD, and the cost of determining CTC is 7920 USD. Sequential chemotherapy of 22 cases of lung cancer progression according to the carboplatin + paclitaxel regimen in the amount of 6 courses is approximately 87548.34 USD. The criterion of economic effectiveness is determined by dividing the amount of prevented economic damage by the amount of funds spent. The amount of damage prevented was 87548.34 USD, and the cost-effectiveness was 87548.34/26083.2=3.36. Thus, for one dollar spent, the savings are about 3.36 dollars, excluding the costs of additional diagnostic measures, including various types of biopsies to confirm the fact of tumor progression, changing chemotherapy regimens and prescribing targeted therapy and immunotherapy, payment for temporary disability and lack of effective patient’s work.
Keywords: lung cancer, circulating tumor cells, adjuvant chemotherapy, cost-effectiveness.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2018 Nov;68(6):394-424. doi: http://dx.doi.org/10.3322/caac.21492
2. Lee JG, Lee CY, Bae MK, Byun CS, Kim DJ, Chung KY. Changes in the demographics and prognoses of patients with resected non-small cell lung cancer: a 20-year experience at a single institution in Korea. Journal of Korean Medical Science. 2012 Dec;27(12):1486-1490. doi: http://dx.doi.org/10.3346/jkms.2012.27.12.1486
3. Okeanov AE, Moiseev PI, Levin LF, Evmenenko AA, Stremous MV, Ipatiĭ TB; Polyakov SL, red. Rak v Cancer in Belarus: figures and facts. Analysis of the data of the Belarusian Cancer Registry for 2012-2021. Minsk, RB: NBB; 2023. 296 р. (In Russ.).
4. Park SY, Lee HS, Jang HJ, Lee GK, Chung KY, Zo JI. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. The Annals of Thoracic Surgery. 2011 Jun;91(6):1668-1673. doi: http://dx.doi.org/10.1016/j.athoracsur.2010.12.028
5. Goldstraw P, Crowley J, Chansky K, Dorothy GJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of Thoracic Oncology. 2007 Aug;2(8):706-714. doi: http://dx.doi.org/10.1097/JTO.0b013e31812f3c1a
6. Park SY, Lee JG, Kim J, Byun GE, Bae MK, Lee CY, et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. Journal of Cardiothoracic Surgery. 2013 Jun:8:151. doi: http://dx.doi.org/10.1186/1749-8090-8-151
7. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted Therapy in Advanced Non-small Cell Lung Cancer: Current Advances and Future Trends. Journal of Hematology and Oncology. 2021 Jul;14(1):108. doi: http://dx.doi.org/10.1186/s13045-021-01121-2
8. Lyasnikov KA, Shlyakhtunov EA. Circulating tumor cells expressing survivin (BIRC5) mRNA as a prognostic marker in radically operated patients with stage I-II non-small cell lung cancer. Evraziiskii Onkologicheskii Zhurnal. 2024;12(1):73-84. (In Russ.). doi: http://dx.doi.org/10.34883/PI.2024.12.1.025
9. Wankhede D, Grover S, Hofman P. Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022 Dec;14(24):6112. doi: http://dx.doi.org/10.3390/cancers14246112
10. Registers of UP «Center for Expertise and Testing in Healthcare»: [sait]. URL: https://www.rceth.by/Refbank/reestr_lekarstvennih_sredstv [Accessed 16th June 2025]. (In Russ.)
11. M-vo zdravookhraneniya Resp Belarus'; Anufreenok IV, Artemova NA, Akhmed NN, Baranov AYu, Barmotko MA, Grachev YuN, i dr. Algorithms of diagnostics and treatment of malignant neoplasms: klin protokol. Minsk, RB: Professional'nye izdaniya; 2019. 613 р. (In Russ.)
12. Sakurai F, Narii N, Tomita K, Togo S, Takahashi K, Machitani M, et al. Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus. Molecular Therapy. Methods and Clinical Development. 2016 Mar:3:16001. doi: http://dx.doi.org/10.1038/mtm.2016.1
13. Kölbl AC, Jeschke U, Andergassen U. The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells. International Journal of Molecular Sciences. 2016 Aug;17(8):1308. doi: http://dx.doi.org/10.3390/ijms17081308
Submitted 01.04.2025
Accepted 13.06.2025
Information about authors:
Kanstantsin A. Liasnikau – senior lecturer of the Chair of Oncology with the courses of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0001-5649-4044, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.;
Y.A. Shliakhtunou – Doctor of Medical Sciences, associate professor, Head of the Chair of Oncology with the courses of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, https://orcid.org/0000-0002-5906-5373
